Correspondence  |   January 2011
Opioid Modeling of Central Respiratory Drive Must Take Upper Airway Obstruction into Account
Author Affiliations & Notes
  • Frank J. Overdyk, M.S.E.E., M.D.
  • *Medical University of South Carolina, Charleston, South Carolina.
Article Information
Correspondence   |   January 2011
Opioid Modeling of Central Respiratory Drive Must Take Upper Airway Obstruction into Account
Anesthesiology 1 2011, Vol.114, 219-220. doi:10.1097/ALN.0b013e3181fef383
Anesthesiology 1 2011, Vol.114, 219-220. doi:10.1097/ALN.0b013e3181fef383
To the Editor:
The elegant modeling of the dynamic effects of remifentanil on respiratory depression by Olofsen et al  . is a useful contribution to our understanding of opioid effects on respiratory control.1 The authors' incorporation of non–steady state changes in opioid concentration and the addition of propofol to induce apnea help in their goal to reproduce real-life conditions in patients receiving opioids and sedatives. This is particularly relevant when considering morbidity and mortality incurred by patients in general care ward settings who receive opioids and sedatives.2 However, we believe that the model neglects important considerations that simulate real-life clinical situations relating to predisposed patients whose depth of sedation is sufficient to induce loss of consciousness and upper airway obstruction.
Olofsen et al  . used end-tidal carbon dioxide (ETco2) and remifentanil concentrations as inputs to the model and measured ventilation as an output. The study's stated objective is to build a model that predicts apnea at finite opioid and hypnotic concentrations under dynamic conditions. Our concern is that at concentrations of sedation commensurate with loss of responsiveness, as occurred in this study, partial or complete airway collapse could preclude sampled ETco2from being an accurate reflection of the arterial carbon dioxide, and thereby a valid input to the model. As it stands, the model assumes a patent upper airway. The authors acknowledge that, close to apnea, the ETco2, used by the model to set the ventilation gain G (equation 6), is likely to be falsely low. The authors account for the inaccuracy of this model input by assigning a residual error to the ETco2and modeling it as a probability density function, in addition to ignoring values less than 37.5 torr. Low and unpredictable ETco2values are common in the periapneic period, as shown during the 15-min breathing after the period of apnea in 8 of 10 study subjects receiving remifentanil and propofol (fig. 3, original article). It is feasible that an upper airway obstructive component could contribute to these events. Consequently, the model could break down in obstruction-prone subjects for both the ETco2input (fig. 5F, original article) and minute ventilation (fig. 5E, original article) output during the periapneic period, the precise time for which the model is designed to provide insights.
Hillman et al  . have shown that an abrupt increase in the tendency of the upper airway to collapse at the point of loss of consciousness with propofol in healthy volunteers can be attributed to a precipitate decrease in tone of the primary upper airway dilator, the genioglossus muscle.3 Hajiha et al  . recently demonstrated that opioids cause a dose-related suppression of tonic brainstem stimulatory input to the genioglossus in rats.4 Thus, apart from their suppression of central respiratory drive, opioids and other sedatives can also precipitate upper airway obstruction. The authors use the term apnea  (cessation of airflow) throughout the article as synonymous with suppression central respiratory drive (a central apnea), without considering obstruction (an obstructive apnea). This is an important omission, and the distinction is critical in understanding the time course and relative contributions of upper airway collapse and reduced central respiratory drive to ventilatory failure. It has important implications for our ability to monitor, diagnose, and prevent respiratory decompensation. Thus, ambiguity in the models' critical inputs during the periapneic periods and failure to account for airway obstruction in modeling respiratory responses to opioid/propofol infusion detract from its use.
We believe the model would be improved by including components that account for the complex interactions between the respiratory control mechanisms and airway patency, as eloquently described by Younes.5 Consistent with standard control theory, we would divide the overall (closed-loop) gain of the system into a controller gain and a plant gain. White describes controller gain as the ventilatory responsiveness to hypercapnia or hypoxia, whereas plant gain reflects the effectiveness of any given concentration of ventilatory drive in eliminating carbon dioxide.6 As obstructive hypopneas and apneas develop, a ramped-up controller gain from accumulating Paco2may be attenuated by a negative plant gain from an obstructed airway. In these patients, the ability to rescue themselves from a fatal decompensation, either through a central nervous system arousal or sufficient chemical drive, to cause reflex opening of their airway is a tenuous dynamic that only can be simulated by a model that includes all these components. A metric relating to propensity for upper airway obstruction, perhaps related to critical closing pressure, should be among these.3,7 We also commend the approach of Bouillon et al  ., who uses Paco2as the dependent variable in modeling remifentanil-induced ventilatory depression, with a method that takes carbon dioxide kinetics into account.8 
We are keen to encourage such an approach because root-cause analysis of a case series of postoperative patients found dead in bed on the ward by one of us (F.O.) found serosanginous pulmonary edema not to be an uncommon autopsy finding. Although nonspecific, a potential explanation for this finding is negative pressure pulmonary edema secondary to upper airway obstruction, with fatal consequences.
*Medical University of South Carolina, Charleston, South Carolina.
Olofsen E, Boom M, Nieuwenhuijs D, Sarton E, Teppema L, Aarts L, Dahan A: Modeling the non-steady state respiratory effects of remifentanil in awake and propofol-sedated healthy volunteers. Anesthesiology 2010; 112:1382–95Olofsen, E Boom, M Nieuwenhuijs, D Sarton, E Teppema, L Aarts, L Dahan, A
Overdyk FJ: Postoperative opioids remain a serious patient safety threat. Anesthesiology 2010; 113:259–60Overdyk, FJ
Hillman DR, Walsh JH, Maddison KJ, Platt PR, Kirkness JP, Noffsinger WJ, Eastwood PR: Evolution of changes in upper airway collapsibility during slow induction of anesthesia with propofol. Anesthesiology 2009; 111:63–71Hillman, DR Walsh, JH Maddison, KJ Platt, PR Kirkness, JP Noffsinger, WJ Eastwood, PR
Hajiha M, DuBord MA, Liu H, Horner RL: Opioid receptor mechanisms at the hypoglossal motor pool and effects on tongue muscle activity in vivo  . J Physiol 2009; 587:2677–92Hajiha, M DuBord, MA Liu, H Horner, RL
Younes M: Role of respiratory control mechanisms in the pathogenesis of obstructive sleep disorders. J Appl Physiol 2008; 105:1389–405Younes, M
White DP: Pathogenesis of obstructive and central sleep apnea. Am J Respir Crit Care Med 2005; 172:1363–70White, DP
Eastwood PR, Szollosi I, Platt PR, Hillman DR: Comparison of upper airway collapse during general anaesthesia and sleep. Lancet 2002; 359:1207–9Eastwood, PR Szollosi, I Platt, PR Hillman, DR
Bouillon T, Bruhn J, Radu-Radulescu L, Andresen C, Cohane C, Shafer SL: A model of the ventilatory depressant potency of remifentanil in the non-steady state. Anesthesiology 2003; 99:779–87Bouillon, T Bruhn, J Radu-Radulescu, L Andresen, C Cohane, C Shafer, SL